Unusual & serious adverse effects of SSRIs: Recognition & management

Journal of Psychosocial Nursing and Mental Health Services

Volumn 45, Issue 3, 2007, Pages 15-18

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247514424     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20070301-05     Document Type: Review

References (19)

1. Andreescu, C., Mulsant, B.H., Rothschild, A.J., Flint, A.J., & Meyers, B.S. (2006). Pharmacotherapy of major depression with psychotic features: What is the evidence? Psychiatric Annals, 36, 31-38.
2. Chahine, L.M., & Chemali, Z.N. (2006). Restless legs syndrome: A review. CNS Spectrums, 11, 511-520.
3. Coogan, P.F. (2006). Review of the epidemiological literature on antidepressant use and breast cancer risk. Expert Review of Neurotherapeutics, 6, 1363-1374.
4. Damsa, C., Bumb, A., Bianchi-Demicheli, P., Vidailhet, P., Sterck, R., Andreoli, A., et al. (2004). "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: A clinical review. Journal of Clinical Psychiatry, 65, 1064-1068.
5. Egger, C., Muehlbacher, M., Nickel, M., Geretsegger, C., & Stuppaeck, C. (2006). A review on hyponatremia associated with SSRIs, reboxetine, and venlafaxine. International Journal of Psychiatry in Clinical Practice, 10, 17-26.
6. Ener, R.A., Meglathery, S.B., Van Decker, W.A., & Gallagher, R.M. (2003). Serotonin syndrome and other serotonergic disorders. Pain Medicine, 4, 63-74.
7. Finfgeld, D.L. (2004). Serotonin syndrome and the use of SSRIs. Journal of Psychosocial Nursing and Mental Health Services, 42(2), 16-20.
8. Howland, R.H., & Thase, M.E. (2002). Therapeutic armamentarium. In H. D'haenen, J.A. Den Boer, & P. Willner (Eds.), Biological psychiatry (Vol. 2, pp. 861-875). London, UK: Wiley & Sons.
9. Huang, V., & Gortney, J.S. (2006). Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmocotherapy, 26, 1784-1793.
10. Kaufman, K.R., Levitt, M.J., Schlitz, J.F., & Sunderram, J. (2006). Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: Case analysis. Annals of Clinical Psychiatry, 18, 201-204.
11. Levy, R., & Czernecki, V. (2006). Apathy and the basal ganglia. Journal of Neurology, 253(Suppl. 7), vii54-vii61.
12. Masand, P.S., & Gupta, S. (1999). Selective serotonin-reuptake inhibitors: An update. Harvard Review of Psychiatry, 7, 69-84.
13. Nieuwstraten, C., Labiris, N.R., & Hoibrook, A. (2006). Systematic overview of drug interactions with antidepressant medications. Canadian Journal of Psychiatry, 51, 300-316.
14. Opbroek, A., Delgado, P.L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F.A., et al. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction: Do SSRIs inhibit emotional responses? International Journal of Neuropsychopharmacology, 5, 147-151.
15. Rothman, R.B., & Baumann, M.H. (2006). Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs. Annals of the New York Academy of Sciences, 1074, 245-260.
16. Schillevoort, I., van Puijenbroek, E.P., de Boer, A., Roos, R.A., Jansen, P.A., & Leufkens, H.G. (2002). Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: A case-control study using spontaneous reports. International Clinical Psychopharmacology, 17, 75-79.
17. Stahl, S.M. (2005). Antidepressant treatment of psychotic major depression: Potential role of the sigma receptor. CNS Spectrums,10, 319-323.
18. Tepper, S.J., & Millson, D. (2003). Safety profile'of the triptans. Expert Opinion on Drug Safety, 2, 123-132.
19. Yuan, Y., Tsoi, K., & Hunt, R.H. (2006). Selective serotonin reuptake inhibitors and risk of upper GI bleeding: Confusion or confounding? American Journal of Medicine, 119, 719-727.